Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
APL180 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| APL180 (first dose level) | EXPERIMENTAL | - |
| APL180 (second dose level) | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| APL180 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Male and female CHD or CHD equivalent patients * Body mass index (BMI) must be within the range of 20 to 35 kg/m2, * Patient must have been on a stable statin therapy for \>8 weeks prior to first dose except for the statin intolerant patients. Exclusion criteria: * Pregnancy...
APL180 is an investigational small molecule being developed for Coronary Heart Disease. It is a Phase 1 drug candidate that has been studied in clinical trials for this condition. The drug is not approved and remains in clinical development.
APL180 is being developed by Novartis AG, a global pharmaceutical company listed on the stock exchange under the ticker NVS. The drug is currently in Phase 1 clinical development for Coronary Heart Disease.
APL180 is in Phase 1 clinical development. It has completed two Phase 1 trials, with a total of 280 participants enrolled. The drug is investigational and has not been approved for any use.
APL180 has completed two Phase 1 trials: NCT00568594, which enrolled 176 participants including healthy volunteers and patients with Coronary Heart Disease, and NCT00907998, which enrolled 104 participants. Both trials were completed and evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics.
APL180 is the primary name for this investigational drug candidate. No alternative names have been reported for this compound in the available clinical trial information.